Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Wyeth Pharmaceuticals and Progenics Pharmaceuticals today announced that they have entered into an exclusive, worldwide agreement for the joint development and…
Paul J. Maddon, MD, PhD, Progenics CEO: 'The approval of RELISTOR is a transformative event for Progenics Pharmaceuticals. This is our first U.S. product…
On April 1, 2008, Progenics and Wyeth announced that Health Canada has approved methylnaltrexone for the treatment of opioid-induced constipation. It was later…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Wyeth and Progenics enter License and Co-Development Agreement for methylnaltrexone (later Relistor) - opioid-induced constipation. Strategically notable; deal value undisclosed in source.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Wyeth Pharmaceuticals / Progenics Pharmaceuticals, Inc. (this deal) | 2005 | $416M | — |
| Wyeth Pharmaceuticals / Zealand Pharma A/S | 2005 | — | — |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2005 deals